The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

How azacitidine works

Bookmark and Share

ASH 50th annual meeting 2008

6 - 9 Dec 2008

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 19 Feb 2009
Views: 20688
Rating:
Save
Dr Lewis Silverman - Myelodysplastic Syndrome & Myeloproliferative Disease Center, New York
How azacitidine / vidaza works, epigenetics and vidaza, the difference vidaza makes for patients. Interviewed at ASH 2008.

Related Videos

Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
Significance of gut microbiota in patients receiving CAR T cell immunotherapy ( Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA )
17 Dec 2021
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with ...
Prof Meral Beksac and Prof Roman Hájek
INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma ( Prof Meral Beksac and Prof Roman Hájek )
15 Dec 2021
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-lin...
Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients ( Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )
14 Dec 2021
Triple class refractory multiple myeloma
Prof Joseph Mikhael - Translational Genomics Research Institute (TGen), Phoenix,...
Triple class refractory multiple myeloma ( Prof Joseph Mikhael - Translational Genomics Research Institute (TGen), Phoenix, USA )
10 Nov 2021
Novel therapies in multiple myeloma
Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
12 Jul 2021
EHA 2021: Latest in immunotherapy for R/R multiple myeloma
Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cav...
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation